Bispecific γδ T Cell Antibody Development Services

With the rapid advances in bioengineering during the past decades, Creative Biolabs has developed an advanced engineering platform to provide novel and well-behaving bispecific γδ T cell antibodies for diverse therapeutic applications.

What is Bispecific Antibody?

Generally, an antibody mono specifically recognizes and binds to an antigen molecule through the fragment antigen-binding (Fab) variable region. Here, a bispecific antibody is engineered to simultaneously bind to two distinct epitopes or antigens, triggering enhanced effector bio-functions. Manufactured bispecific antibodies by recombinant DNA methodology are multiform and broadly divided into two categories: those containing an Fc region named as IgG-like bispecific antibodies and those without an Fc region are non-IgG-like bispecific antibodies.

By binding to target antigens, bispecific antibodies induce a variety of bioactivities, such as recruitment and activation of immunocytes, blocking receptor signaling, cytotoxicity, and targeted delivery. Bispecific antibodies have been extensively applied for preclinical studies and clinical treatments, especially for cancer immunotherapy. Currently, Blinatumomab, Catumaxomab, and Emicizumab are representatives of approved bispecific antibodies for human disease therapy, and numbers of bispecific antibodies are under evaluation in the clinical stage for the treatment of both cancers and non-cancer indications.

Fig.1 Examples of obligate mechanisms of action of bispecific antibodies. (Labrijn, 2019)

Bispecific Antibody: a New Strategy for γδ T Cell Therapy Improvement

γδ T cell, a minor group of T lymphocytes with a characterized γδ T-cell receptor (γδTCR), has drawn great concentration for cancer immunotherapy in recent years. γδ T cells, such as Vγ9Vδ2 T cells, sensitively recognize phosphoantigens derived from tumor cells and infiltrate tumor cells, by which γδ T cells secret a variety of cytokines and cytotoxic molecules, and lyse tumor cells by antibody-dependent cellular cytotoxicity (ADCC).

To date, multiple approaches have been explored to improve the anti-tumor efficacy of γδ T cell immunotherapy. The bispecific antibody has been demonstrated as an engager to bind to T cells and tumor cells, which effectively enhances the targeting and cytotoxic activity of tumor cells. Published literature performed that bispecific antibodies against CD3 or Vγ9 TCR on the surface of γδ T cells and Her2 significantly enhanced the cytotoxicity of γδ T cells to pancreatic ductal adenocarcinoma. And Vγ9Vδ2 TCR and epidermal growth factor receptor (EGFR) bispecific sdAbs effectively lyse tumor cells both in vivo and in vitro.

Fig.2 Bispecific γδ T cell antibody.

Bispecific γδ T Cell Antibody Development Services

Currently, both bispecific antibody and γδ T cell therapy have made achievements in human disease treatment. Creative Biolabs has always been known as an excellent supplier of various antibodies. Based on enriched experience in antibody engineering and γδ T cell therapy, we offer custom bispecific γδ T cell antibody development services for the treatment of diverse tumors and cancers.

For details, please directly contact us, we will offer you the most tailored solutions and support as soon as possible.

Reference

1. Labrijn, A.F., et al. Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery. 2019, 18(8): 585-608.